FDA WARNS OF LINK BETWEEN BISPHOSPHONATES AND FEMUR FRACTURES
New York, NY October 14, 2010
On October 13, 2010 The U.S. Food and Drug Administration (FDA) warned patients and health care providers about the possible risk of atypical thigh bone (femur) fracture in patients who take bisphosphonates, such as Fosamax, a class of drugs used to prevent and treat osteoporosis. Unfortunately, this new warning comes too late for those who have already suffered from these debilitating injuries. The lawyers at Bernstein Liebhard LLP are currently investigating claims against the manufacturers of these drugs, and are offering free and confidential legal consultations to individuals who took these bone drugs and fractured their femoral bone.
Bisphosphonates & Femur Fractures
Bisphosphonates include such drugs as Fosamax, Fosamax Plus D, and their generic products. They are typically prescribed to treat the loss of bone mass in people with osteoporosis. Atypical femur fractures, a rare but serious type of thigh bone fracture, have been predominantly reported in patients taking bisphosphonates. The FDA is highlighting that these fractures may be related to use of bisphosphonates for longer than five years.
“The FDA is continuing to evaluate data about the safety and effectiveness of bisphosphonates when used long-term for osteoporosis treatment,” said RADM Sandra Kweder, M.D., deputy director, Office of New Drugs in the FDA’s Center for Drug Evaluation and Research. “In the interim, it’s important for patients and health care professionals to have all the safety information available when determining the best course of treatment for osteoporosis.”
The FDA’s warning [add link to http://www.consumerinjurylawyers.com/fosamax/Femur-Fracture-Warning.html follows a March 10, 2010, Drug Safety Communication announcing the FDA’s ongoing safety review of bisphosphonate use and the occurrence of atypical femur fractures. The FDA has since reviewed all available data on bisphosphonate use, including data summarized in the American Society for Bone Mineral Research Task Force report. The report recommended additional product labeling, better identification and tracking of patients experiencing these breaks, and more research to determine whether and how these drugs cause the serious but uncommon fractures.
The FDA recommends that health care professionals be aware of the possible risk in patients taking bisphosphonates and consider periodic reevaluation of the need for continued bisphosphonate therapy for patients who have been on bisphosphonates for longer than five years.
Legal Help for a Fosamax Femur Fracture
If you or a loved one have suffered a Fosamax femur fracture, you may be entitled to file a lawsuit seeking compensation for your medical bills, pain and suffering, lost wages, and other injuries. Contact a lawyer at Bernstein Liebhard LLP at (877) 779-1414 or [email protected] for a confidential and free case evaluation or visit our consumer advocacy website, www.ConsumerInjuryLawyers.com.
Since 1993, Bernstein Liebhard has pursued hundreds of cases on behalf of injured consumers and shareholders, recovering almost $3 billion for our clients. For eight consecutive years, The National Law Journal has named the Firm as one of the top plaintiff’s litigation firms in the country.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Seth Ottensoser, Esq.